Panel Discussion: Are we measuring FR&D success the right way?

Panellists in this video:
♦ Ms Lakshmipriya Nair, Assistant Editor, Express Pharma (MODERATOR)
♦ Dr Parva Purohit, Sr VP – R&D, Amneal Pharmaceuticals
♦ Dr Amarender Reddy Donthidi, VP & Head R&D (Injectables and Ophthalmics), Amneal Pharmaceuticals
♦ Mr Ravikiran Bhabad, Deputy GM – OSD, FTF Pharma (Subsidiary of Shilpa Medicare)

Key Highlights:
[1] Faster time-to-market must be balanced with stringent quality standards throughout product development.

[2] R&D teams need greater agility to adapt to changing market demand, priorities and regulatory requirements.

[3] Successful drug development extends beyond commercialisation, with every stage from R&D to scale-up playing a critical role.

[4] Robust scale-up and regulatory processes are essential to prevent quality issues and safeguard patient safety.